Levetiracetam intravenous infusion: A randomized, placebo-controlled safety and pharmacokinetic study

Epilepsia

Volumn 47, Issue 7, 2006, Pages 1128-1135

  Ramael, Steven ^a   Daoust, Agnès ^b   Otoul, Christian ^b   Toublanc, Nathalie ^b   Troenaru, Mona ^b   Lu, Zhihong ^b   Stockis, Armel ^b  

^a Stuivenberg General Hospital   (Belgium)

^b UCB PHARMA   (Belgium)

Author keywords

Epilepsy; Intravenous infusion; Levetiracetam; Pharmacokinetics; Safety

Indexed keywords

ETIRACETAM; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BALANCE DISORDER; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUNK SENSATION; DYSGEUSIA; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INFUSION RATE; MALE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; THIRST; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; ANTICONVULSANTS; AREA UNDER CURVE; BLOOD PRESSURE; DISORDERS OF EXCESSIVE SOMNOLENCE; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FATIGUE; FEMALE; HALF-LIFE; HEADACHE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PIRACETAM; PLACEBOS; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 33746115639     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2006.00586.x     Document Type: Article

References (32)

1. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004;101:9861-6.
2. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002;43:9-18.
3. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 2001;306:5-8.
4. Ängehagen M, Margineau DG, Ben-Menachem E, et al. Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons. Neuroreport 2003;14:471-5.
5. Cataldi M, Lariccia V, Secondo A, et al. The antiepileptic drug levetiracetam decreases the inositol 1,4,5-trisphosphate-dependent [Ca2+]I increase induced by ATP and bradykinin in PC12 cells. J Pharmacol Exp Ther 2005;313:720-30.
6. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002;136:659-72.
7. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-42.
8. Boon P, Chauvel P, Pohlmann-Eden B, et al. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res 2002;48:77-89.
9. Ben-Menachem E, Falter U, for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000;41:1276-83.
10. Shorvon SD, Löwenthal A, Janz D, et al., for the European Levetiracetam Study Group. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000;41:1179-86.
11. Morrell MJ, Leppik I, French J, et al. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 2003;54:153-61.
12. -1 in adult patients with refractory epilepsy. Seizure 2003;12:141-9.
13. French J, Arrigo C. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia 2005;46:324-6.
14. Ben-Menachem E, Edrich P, Van Vleymen B, et al. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 2003;53:56-64.
15. Krakow K, Walker M, Otoul C, et al. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001;56:1772-4.
16. Ramael S, De Smedt F, Toublanc N, et al. Levetiracetam intravenous infusion: safety, tolerability and bioavailability versus oral tablet. Epilepsia 2005;46(suppl 6):268. Abstract 819.
17. Coupez R, Nicolas J-M, Browne TR. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia 2003;44:171-8.
18. Meta C, Patel N. Proc-StatXact 4 for SAS Users. Cytel Software Corporation, Cambridge, MA, 1999.
19. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000;17:1278-83.
20. Briggs DE, French JA. Levetiracetam safety profiles and tolerability in epilepsy patients. Exp Opin Drug Safety 2004;3:415-24.
21. Baulac M, Voss G, Krygier C, et al., and the LEV N01166 Study Group. Safety profile of levetiracetam intravenous infusion (1000-3000 mg/d b.i.d. administration) in patients with partial-onset seizures. Presented at American Epilepsy Society 2005 Annual Meeting; December 2-6, 2005; Washington, DC. Poster 2.234.
22. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam, a new antiepileptic drug. Epilepsy Res 2001;47:77-90.
23. Harden C. Safety profile of levetiracetam. Epilepsia 2001;42(suppl 4):36-9.
24. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia 2001;42(suppl 4):24-7.
25. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85:77-85.
26. Gidal BE, Baltes E, Otoul C, et al. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res 2005;64:1-11.
27. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004;43:707-24.
28. Coupez R, Straetemans R, Sehgal G, et al. Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets. J Clin Pharmacol 2003;43:1370-6.
29. Perucca E, Gidal BE, Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res 2003;53:47-56
30. Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 2002;43:697-702.
31. Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res 2001;46:93-9.
32. Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res 2001;47:55-63.